Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05446_nanopub.RAj9yzdOf7VRWs-7wetQgFZ1CWmyUSqgJ1AAbNGCE2Ywk#assertion>. }
Showing items 1 to 14 of
14
with 100 items per page.
- drugbank:DB05446 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05446 label "LJP 1082 [drugbank:DB05446]" assertion.
- drugbank:DB05446 seeAlso DB05446 assertion.
- drugbank:DB05446 description "LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to Ã2 GP1. LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. Antibody-mediated thrombosis, also called antiphospholipid syndrome (APS), is a blood clotting disorder. Patients with high levels of anticardiolipin antibodies (ACA) have an increased risk of stroke, heart attack, deep vein thrombosis, and recurrent fetal loss. The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. To date, our scientists have shown that approximately 90% of patients studied with antibody-mediated thrombosis have antibodies that bind to this region." assertion.
- drugbank:DB05446 identifier "drugbank:DB05446" assertion.
- drugbank:DB05446 title "LJP 1082" assertion.
- drugbank:DB05446 drugbank_vocabulary:x-pubchemcompound pubchem.compound:1082 assertion.
- drugbank:DB05446 drugbank_vocabulary:x-chemspider chemspider:1052 assertion.
- drugbank:DB05446 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05446 drugbank_vocabulary:drugbank-id "DB05446" assertion.
- drugbank:DB05446 bio2rdf_vocabulary:x-identifiers.org DB05446 assertion.
- drugbank:DB05446 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05446" assertion.
- drugbank:DB05446 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05446 bio2rdf_vocabulary:identifier "DB05446" assertion.